SEATTLE--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) today announced positive data from a phase I clinical trial of SGN-35, an antibody-drug conjugate (ADC), demonstrating multiple objective responses at well-tolerated doses in patients with Hodgkin lymphoma and other CD30-positive hematologic malignancies. The data were presented during a poster discussion session at the American Society of Clinical Oncology (ASCO) 44th Annual Meeting being held in Chicago, Illinois.
